跳至主要内容
临床试验/NL-OMON48170
NL-OMON48170已完成不适用

An open-label, mass balance study to investigate the absorption, metabolism and excretion of [14C]-EYP001a after a single oral dose to healthy male subjects - CS0315 Enyo

ENYO Pharma SA0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Able to provide informed consent to participate in this study after reading
  • the participant information sheet and informed consent form and after having
  • the opportunity to discuss the study with the Investigator or designee.
  • 2. Healthy and free from clinically significant illness or disease as
  • determined by medical history, physical examination, laboratory and other tests
  • at Screening.
  • 3. Male Caucasian subjects, aged 18 to 60 years (inclusive) at Screening.

排除标准

  • 1. Any finding of the medical examination (including blood pressure, pulse rate
  • and ECG) deviating from normal and of clinical relevance.
  • 2. History or current clinically significant gastrointestinal, hepatic, renal,
  • respiratory, cardiovascular, metabolic, immunologic, hormonal disorders.
  • 3. History of any major surgery within the last 4 weeks before participation in
  • this study or any bone fracture within the last 2 months.

研究者

相似试验

An open-label, mass balance study to investigate the... | 临床试验